

(19)

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

EP 0 729 951 A1

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication  
04.09.1996 Bulletin 1996/36

(51) Int Cl<sup>6</sup> C07D 295/08, C07C 43/295,  
C07C 47/575, A61K 31/445

(21) Application number 96300877.6

(22) Date of filing 09.02.1996

(84) Designated Contracting States  
AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT  
SE

(72) Inventor Palkowitz, Alan David  
Carmel, Indiana 46032 (US)


(30) Priority 28.02.1995 US 395950

(74) Representative Hudson, Christopher Mark et al  
Lilly Industries Limited  
European Patent Operations  
Erl Wood Manor  
Windlesham Surrey GU20 6PH (GB)

(71) Applicant ELI LILLY AND COMPANY  
Indianapolis, Indiana 46285 (US)

(54) Naphthyl compounds, intermediates, compositions, and methods

(57) The present invention provides pharmaceutically active compounds formula I



wherein

R<sup>1</sup> is -H, -OH, -O(C<sub>1</sub>-C<sub>4</sub> alkyl), -OCOC<sub>6</sub>H<sub>5</sub>, -OCO(C<sub>1</sub>-C<sub>6</sub> alkyl), or -OSO<sub>2</sub>(C<sub>2</sub>-C<sub>6</sub> alkyl),

R<sup>2</sup> is -H, -OH, -O(C<sub>1</sub>-C<sub>4</sub> alkyl), -OCOC<sub>6</sub>H<sub>5</sub>, -OCO(C<sub>1</sub>-C<sub>6</sub> alkyl), -OSO<sub>2</sub>(C<sub>2</sub>-C<sub>6</sub> alkyl), or halo,


R<sup>3</sup> is 1-piperidiny, 1-pyrrolidiny, methyl-1-pyrrolidiny, dimethyl-1-pyrrolidino, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino, and

n is 2 or 3, and

or a pharmaceutically acceptable salt thereof

Also provided are compounds of formula II

EP 0 729 951 A1



II

wherein

R<sup>1a</sup> is -H or -OR<sup>5</sup> in which R<sup>5</sup> is a hydroxy protecting group

R<sup>2a</sup> is -H, halo, or -OR<sup>6</sup> in which R<sup>6</sup> is a hydroxy protecting group, and

R<sup>4</sup> is -OH or -CHO,

or a pharmaceutically acceptable salt thereof

Further provided are pharmaceutical compositions of compounds of formula I, and methods of using formula I compounds for, *inter alia*, alleviating the symptoms of post menopausal syndrome and hormonally-dependent cancer, particularly, breast cancer

## Description

This invention relates to the fields of pharmaceutical and organic chemistry and provides novel naphthyl compounds which are useful for the treatment of the various medical indications associated with post-menopausal syndrome and uterine fibroid disease, endometriosis, and aortal smooth muscle cell proliferation. The present invention further relates to intermediate compounds useful for preparing the pharmaceutically active compounds of the present invention and pharmaceutical compositions.

"Post-menopausal syndrome" is a term used to describe various pathological conditions which frequently affect women who have entered into or completed the physiological metamorphosis known as menopause. Although numerous pathologies are contemplated by the use of this term, three major effects of post-menopausal syndrome are the source of the greatest long-term medical concern: osteoporosis, cardiovascular effects such as hyperlipidemia, and estrogen-dependent cancer, particularly breast and uterine cancer.

Osteoporosis describes a group of diseases which arise from diverse etiologies, but which are characterized by the net loss of bone mass per unit volume. The consequence of this loss of bone mass and resulting bone fracture is the failure of the skeleton to provide adequate structural support for the body. One of the most common types of osteoporosis is that associated with menopause. Most women lose from about 20% to about 60% of the bone mass in the trabecular compartment of the bone within 3 to 6 years after the cessation of menses. This rapid loss is generally associated with an increase of bone resorption and formation. However, the resorptive cycle is more dominant and the result is a net loss of bone mass. Osteoporosis is a common and serious disease among post-menopausal women.

There are an estimated 25 million women in the United States alone, who are afflicted with this disease. The results of osteoporosis are personally harmful and also account for a large economic loss due to its chronicity and the need for extensive and long term support (hospitalization and nursing home care) from the disease sequelae. This is especially true in more elderly patients. Additionally, although osteoporosis is not generally thought of as a life threatening condition, a 20% to 30% mortality rate is related with hip fractures in elderly women. A large percentage of this mortality rate can be directly associated with post-menopausal osteoporosis.

The most vulnerable tissue in the bone to the effects of post-menopausal osteoporosis is the trabecular bone. This tissue is often referred to as spongy or cancellous bone and is particularly concentrated near the ends of the bone (near the joints) and in the vertebrae of the spine. The trabecular tissue is characterized by small osteoid structures which interconnect with each other, as well as the more solid and dense cortical tissue which makes up the outer surface and central shaft of the bone. This inter-connected network of trabeculae gives lateral support to the outer cortical structure and is critical to the bio-mechanical strength of the overall structure. In post-menopausal osteoporosis, it is primarily the net resorption and loss of the trabeculae which leads to the failure and fracture of bone. In light of the loss of the trabeculae in post-menopausal women, it is not surprising that the most common fractures are those associated with bones which are highly dependent on trabecular support, e.g. the vertebrae, the neck of the weight bearing bones such as the femur and the fore-arm. Indeed, hip fracture, colles fractures, and vertebral crush fractures are hall-marks of post-menopausal osteoporosis.

At this time, the only generally accepted method for treatment of post-menopausal osteoporosis is estrogen replacement therapy. Although therapy is generally successful, patient compliance with the therapy is low primarily because estrogen treatment frequently produces undesirable side effects.

Throughout premenopausal time, most women have less incidence of cardiovascular disease than age-matched men. Following menopause, however, the rate of cardiovascular disease in women slowly increases to match the rate seen in men. This loss of protection has been linked to the loss of estrogen and, in particular, to the loss of estrogen's ability to regulate the levels of serum lipids. The nature of estrogen's ability to regulate serum lipids is not well understood, but evidence to date indicates that estrogen can upregulate the low density lipid (LDL) receptors in the liver to remove excess cholesterol. Additionally, estrogen appears to have some effect on the biosynthesis of cholesterol, and other beneficial effects on cardiovascular health.

It has been reported in the literature that post-menopausal women having estrogen replacement therapy have a return of serum lipid levels to concentrations to those of the pre-menopausal state. Thus, estrogen would appear to be a reasonable treatment for this condition. However, the side-effects of estrogen replacement therapy are not acceptable to many women, thus limiting the use of this therapy. An ideal therapy for this condition would be an agent which would regulate the serum lipid level as does estrogen, but would be devoid of the side-effects and risks associated with estrogen therapy.

The third major pathology associated with post-menopausal syndrome is estrogen-dependent breast cancer and to a lesser extent, estrogen-dependent cancers of other organs, particularly the uterus. Although such neoplasms are not solely limited to a post-menopausal women, they are more prevalent in the older, post-menopausal population. Current chemotherapy of these cancers has relied heavily on the use of anti-estrogen compounds such as, for example, tamoxifen. Although such mixed agonist-antagonists have beneficial effects in the treatment of these cancers, and the estrogenic side-effects are tolerable in acute life-threatening situations, they are not ideal. For example, these agents

may have stimulatory effects on certain cancer cell populations in the uterus due to their estrogenic (agonist) properties and they may, therefore be contraproductive in some cases. A better therapy for the treatment of these cancers would be an agent which is an anti-estrogen compound having negligible or no estrogen agonist properties on reproductive tissues

In response to the clear need for new pharmaceutical agents which are capable of alleviating the symptoms of inter alia, post-menopausal syndrome the present invention provides new benzothioophene compounds, pharmaceutical compositions thereof, and methods of using such compounds for the treatment of post-menopausal syndrome and other estrogen-related pathological conditions such as those mentioned below

Uterine fibrosis (uterine fibroid disease) is an old and ever present clinical problem which goes under a variety of names, including uterine fibroid disease, uterine hypertrophy, uterine leiomyomata, myometrial hypertrophy, fibrosis uteri, and fibrotic metritis. Essentially, uterine fibrosis is a condition where there is an inappropriate deposition of fibroid tissue on the wall of the uterus

This condition is a cause of dysmenorrhea and infertility in women. The exact cause of this condition is poorly understood but evidence suggests that it is an inappropriate response of fibroid tissue to estrogen. Such a condition has been produced in rabbits by daily administrations of estrogen for 3 months. In guinea pigs, the condition has been produced by daily administration of estrogen for four months. Further, in rats, estrogen causes similar hypertrophy

The most common treatment of uterine fibrosis involves surgical procedures both costly and sometimes a source of complications such as the formation of abdominal adhesions and infections. In some patients, initial surgery is only a temporary treatment and the fibroids regrow. In those cases a hysterectomy is performed which effectively ends the fibroids but also the reproductive life of the patient. Also, gonadotropin releasing hormone antagonists may be administered, yet their use is tempered by the fact they can lead to osteoporosis. Thus, there exists a need for new methods for treating uterine fibrosis, and the methods of the present invention satisfy that need

Endometriosis is a condition of severe dysmenorrhea, which is accompanied by severe pain, bleeding into the endometrial masses or peritoneal cavity and often leads to infertility. The cause of the symptoms of this condition appear to be ectopic endometrial growths which respond inappropriately to normal hormonal control and are located in inappropriate tissues. Because of the inappropriate locations for endometrial growth, the tissue seems to initiate local inflammatory-like responses causing macrophage infiltration and a cascade of events leading to initiation of the painful response. The exact etiology of this disease is not well understood and its treatment by hormonal therapy is diverse, poorly defined, and marked by numerous unwanted and perhaps dangerous side effects

One of the treatments for this disease is the use of low dose estrogen to suppress endometrial growth through a negative feedback effect on central gonadotropin release and subsequent ovarian production of estrogen; however, it is sometimes necessary to use continuous estrogen to control the symptoms. This use of estrogen can often lead to undesirable side effects and even the risk of endometrial cancer

Another treatment consists of continuous administration of progestins which induces amenorrhea and by suppressing ovarian estrogen production can cause regressions of the endometrial growths. The use of chronic progestin therapy is often accompanied by the unpleasant CNS side effects of progestins and often leads to infertility due to suppression of ovarian function

A third treatment consists of the administration of weak androgens, which are effective in controlling the endometriosis; however, they induce severe masculinizing effects. Several of these treatments for endometriosis have also been implicated in causing a mild degree of bone loss with continued therapy. Therefore, new methods of treating endometriosis are desirable

Smooth aortal muscle cell proliferation plays an important role in diseases such as atherosclerosis and restenosis. Vascular restenosis after percutaneous transluminal coronary angioplasty (PTCA) has been shown to be a tissue response characterized by an early and late phase. The early phase occurring hours to days after PTCA is due to thrombosis with some vasospasms while the late phase appears to be dominated by excessive proliferation and migration of aortal smooth muscle cells. In this disease, the increased cell motility and colonization by such muscle cells and macrophages contribute significantly to the pathogenesis of the disease. The excessive proliferation and migration of vascular aortal smooth muscle cells may be the primary mechanism to the reocclusion of coronary arteries following PTCA, atherectomy, laser angioplasty and arterial bypass graft surgery. See "Intimal Proliferation of Smooth Muscle Cells as an Explanation for Recurrent Coronary Artery Stenosis after Percutaneous Transluminal Coronary Angioplasty," Austin *et al*, *Journal of the American College of Cardiology*, 9, 369-375 (Aug. 1985)


Vascular restenosis remains a major long term complication following surgical intervention of blocked arteries by percutaneous transluminal coronary angioplasty (PTCA), atherectomy, laser angioplasty and arterial bypass graft surgery. In about 35% of the patients who undergo PTCA, reocclusion occurs within three to six months after the procedure. The current strategies for treating vascular restenosis include mechanical intervention by devices such as stents or pharmacologic therapies including heparin, low molecular weight heparin, coumarin, aspirin, fish oil, calcium antagonist, steroids, and prostacyclin. These strategies have failed to curb the reocclusion rate and have been ineffective for the treatment and prevention of vascular restenosis. See "Prevention of Restenosis after Percutaneous Transluminal

Coronary Angioplasty The Search for a 'Magic Bullet', Hermans *et al* *American Heart Journal*, 122 171-187 (July 1991)

In the pathogenesis of restenosis excessive cell proliferation and migration occurs as a result of growth factors produced by cellular constituents in the blood and the damaged arterial vessel wall which mediate the proliferation of smooth muscle cells in vascular restenosis

Agents that inhibit the proliferation and/or migration of smooth aortal muscle cells are useful in the treatment and prevention of restenosis The present invention provides for the use of compounds as smooth aortal muscle cell proliferation inhibitors and thus inhibitors of restenosis

The present invention relates to compounds of formula I



I

wherein

R<sup>1</sup> is -H, -OH, -O(C<sub>1</sub>-C<sub>4</sub> alkyl), -OCOC<sub>6</sub>H<sub>5</sub>, -OCO(C<sub>1</sub>-C<sub>6</sub> alkyl), or -OSO<sub>2</sub>(C<sub>2</sub>-C<sub>6</sub> alkyl).


R<sup>2</sup> is -H, -OH, -O(C<sub>1</sub>-C<sub>4</sub> alkyl), -OCOC<sub>6</sub>H<sub>5</sub>, -OCO(C<sub>1</sub>-C<sub>6</sub> alkyl), -OSO<sub>2</sub>(C<sub>2</sub>-C<sub>6</sub> alkyl), or halo,

R<sup>3</sup> is 1-piperidiny, 1-pyrrolidiny, methyl-1-pyrrolidiny, dimethyl-1-pyrrolidino, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino, and

n is 2 or 3, and

or a pharmaceutically acceptable salt thereof

Also provided by the present invention are intermediate compounds of formula II which are useful for preparing the pharmaceutically active compounds of the present invention, and are shown below



II

wherein

R<sup>1a</sup> is -H or -OR<sup>5</sup> in which R<sup>5</sup> is a hydroxy protecting group

R<sup>2a</sup> is -H, halo, or -OR<sup>6</sup> in which R<sup>6</sup> is a hydroxy protecting group and


R<sup>4</sup> is -OH or -CHO, or a pharmaceutically acceptable salt thereof

The present invention further relates to pharmaceutical compositions containing compounds of formula I, optionally

containing estrogen or progestin and the use of such compounds alone or in combination with estrogen or progestin, for alleviating the symptoms of post-menopausal syndrome particularly osteoporosis, cardiovascular related pathological conditions, and estrogen-dependent cancer. As used herein, the term "estrogen" includes steroidal compounds having estrogenic activity such as, for example 17 $\beta$ -estradiol, estrone, conjugated estrogen (Premarin®), equine estrogen 17 $\beta$ -ethynyl estradiol, and the like. As used herein the term "progestin" includes compounds having progestational activity such as for example progesterone, norethynodrel, norgestrel, megestrol acetate, norethindrone, and the like.

The compounds of the present invention also are useful for inhibiting uterine fibroid disease and endometriosis in women and aortal smooth muscle cell proliferation particularly restenosis in humans.

One aspect of the present invention includes compounds of formula I



wherein

R¹ is -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), or -OSO₂(C₂-C₆ alkyl),

R² is -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), -OSO₂(C₂-C₆ alkyl), or halo,


R³ is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidino, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino, and

n is 2 or 3, and

or a pharmaceutically acceptable salt thereof

General terms used in the description of compounds herein described bear their usual meanings. For example, "C₁-C₆ alkyl" refers to straight or branched aliphatic chains of 1 to 6 carbon atoms including moieties such as methyl, ethyl, propyl, isopropyl, butyl, n-butyl, pentyl, isopentyl, hexyl, isohexyl, and the like. Similarly, the term "C₁-C₄ alkoxy" represents a C₁-C₄ alkyl group attached through an oxygen molecule and include moieties such as, for example, methoxy, ethoxy, n-propoxy, isopropoxy and the like. Of these alkoxy groups methoxy is highly preferred in most circumstances.

The starting material for preparing compounds of the present invention is a compound of formula III



wherein


R¹ᵃ is -H or -OR⁵ in which R⁵ is a hydroxy protecting group, and


R²ᵃ is -H, halo, or -OR⁶ in which R⁶ is a hydroxy protecting group. Compounds of formula III are well known in the art and are prepared essentially as described by Boyle, *et al*, in U.S. Pat. No. 4,910,212 which is herein incorporated by reference. See, also, Collins, D.J., *et al*, *Aust. J. Chem.*, 41, 745-756 (1988), and Collins, D.J., *et al*,

*Aust J Chem*, 37 2279-2294 (1984)

In preparing compounds of the present invention generally, a ketone of formula III is aromatized, providing a phenol of formula IV which is then reacted with a 4-halobenzaldehyde to give a biaryl ether of formula IIa, which, in turn is converted to a phenol of formula IIb. This synthetic route is as shown below in Scheme I, and R<sup>1a</sup> and R<sup>2a</sup> are as defined above

**Scheme I**





In the first step of the present process a compound of formula III is converted to a phenol of formula IV via a three-step protocol, essentially as described by Wang, G, *et al*, *M. Syn. Commun.*, 21.989 (1991). In essence, a formula II ketone is enolized by refluxing a solution of a formula III compound in an appropriate acetate solvent, in the presence of an acid catalyst. The resulting enolacetate is directly converted to a naphtholacetate which is then hydrolyzed to a phenol of formula IV.

In converting a ketone of formula III to its respective enol, various known acid catalysts can be used. Preferably, non-aqueous acids, and particularly, *p*-toluenesulfonic acid is preferred.

Appropriate acetate solvents include, for example, simple alcohol esters of acetate acid, particularly isopropenyl acetate.

When run at reflux, the present reaction takes from about 6 to about 48 hours to complete. The enol product from this reaction is not isolated, but upon completion of the reaction, the resulting solution is treated with an appropriate oxidant and heated to reflux for, optimally, about 1 to about 3 hours.

Appropriate oxidants for this second phase of the first reaction step shown in Scheme I are limited to those known



in the art which can lead to the elimination of a hydrogen atom from a saturated system to give an aromatized system. Such oxidants include, for example, hydrogenation catalysts such as platinum, palladium and nickel, elemental sulfur and selenium and quinones. For the present application, quinone oxidants, especially 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) are preferred. About 1 to 2 equivalents of DDQ per equivalent of substrate will drive the present process phase.

The resulting product of the present phase, a naphtholacetate, is then subjected to hydrolysis to provide a compound of formula IV, thus completing the first process step shown in Scheme I. The present hydrolysis phase is accomplished via either acid or basic hydrolysis of the substrate in a polar protic solvent such as water or one or more solvents containing an alcohol such as methanol or ethanol. A cosolvent such as tetrahydrofuran (THF) or dioxane also may be added to the solution to aid solubility. Appropriate bases for this phase include sodium hydroxide, potassium hydroxide, lithium hydroxide, and the like. Appropriate acids include, for example, hydrochloric acid, methanesulfonic acid, *p*-toluenesulfonic acid, and the like.

This final phase of the first step shown in Scheme I, *supra*, can be run at ambient temperature and runs in a short period of time, typically from 1 to about 12 hours. Completion of the present reaction can be determined via standard chromatographic techniques such as thin layer chromatography.

In the second step of Scheme I, a phenol of formula IV is first reacted with a base, followed by the addition of a 4-halobenzaldehyde in a polar aprotic solvent, under an inert atmosphere such as nitrogen, to give a biarylether of formula IIa. This reaction is well known in the art and is carried out essentially as described by Yeager, G. W., *et al*, *Synthesis*, **63** (1991).

More particularly, 1 equivalent of a formula IV compound is first treated with at least 1 equivalent of an alkali metal hydride or carbonate in an appropriate solvent, followed by a dropwise addition of a 4-halobenzaldehyde in the same solvent as used with the substrate.

Appropriate solvents for this reaction are those solvents or mixture of solvents which remain inert throughout the reaction. N,N-dimethylformamide (DMF), especially the anhydrous form thereof, is preferred.

Preferably, sodium hydride is used as the required base, and 4-fluorobenzaldehyde is used as the preferred 4-halobenzaldehyde.

The temperature employed in this step of the present process should be sufficient to effect completion of this reaction, without encouraging the formation of undesirable byproducts. A preferred temperature range for this reaction is from about 30° C to about 100° C.

Under preferred reaction conditions, a formula IIa compound will be prepared via the preferred process in about 24 to about 48 hours.

The final reaction shown in Scheme I, the conversion of the aldehyde moiety of a formula IIa compound to a phenol group, thus forming a compound of formula IIb, is known in the art as a Bayer-Villiger oxidation. See, e.g., Fiesers, L., *et al*, *Reagents for Organic Synthesis*, **1** 467, Wiley (New York, 1967), Hassall, C. H., *Organic Reactions*, **9** 73-106 (Wiley, New York, 1967).

In general, the present reaction involves the combination of a benzaldehyde with a peracid such as peracetic acid or *m*-chloroperbenzoic acid in an inert solvent such as chloroform or methylenechloride. The product of this reaction, a formate ester, can then be readily hydrolyzed to the desired phenol. See, e.g., Yeager, *et al*, *supra*; Godfrey, I. M., *et al*, *J. Chem. Soc. Perkins Trans. I* 1353 (1974), and Rue, R., *et al*, *Bull. Soc. Chim. Fr.*, 3617 (1970).

For the present reaction, a preferred variation is described by Matsumoto, M., *et al*, *J. Org. Chem.*, **49** 4741 (1984). This method involves combining a benzaldehyde of formula IIa with at least 1 to about 2 equivalents of 30% hydrogen peroxide in an alcohol solvent, and in the presence of a catalytic acid. Under these conditions, the phenol is formed directly, and the need for an additional hydrolysis step is, therefore, eliminated.

The preferred solvent and acid catalyst for the present reaction is methanol and concentrated sulfuric acid, respectively.


Under the preferred reaction conditions, the transformation from a formula IIa compound to a formula IIb compound is complete after stirring for about 12 to about 48 hours at ambient temperatures.

Compounds of formula IIa and IIb collectively are herein depicted as novel intermediate compounds of formula II which are useful for the preparation of pharmaceutically active compounds of formula I of the present invention.

Upon preparation of a formula IIb compound, it is reacted with a compound of formula V



wherein  $R^3$  and  $n$  are as defined above and  $Q$  is a bromo or, preferably, a chloro moiety, to form a compound of formula Ia. The formula Ia compound is then deprotected, when  $R^5$  and/or  $R^6$  hydroxy protecting groups are present, to form a compound of formula Ib. These process steps are shown in Scheme II below.

**Scheme II**

wherein

$R^{1a}$ ,  $R^{2a}$ ,  $R^3$ , and  $n$  are as defined above,  
 $R^{1b}$  is -H or -OH and  
 $R^{2b}$  is -H, -OH, or halo

or a pharmaceutically acceptable salt thereof

In the first step of the process shown in Scheme II, the alkylation is carried out via standard procedures

Compounds of formula V are commercially available or are prepared by means well known to one of ordinary skill  
 55 in the art. Preferably, the hydrochloride salt of a formula V compound, particularly 2-chloroethylpiperidine hydrochloride, is used

Generally, at least about 1 equivalent of formula IIb substrate are reacted with 2 equivalents of a formula V compound in the presence of at least about 4 equivalents of an alkali metal carbonate, preferably cesium carbonate, and

an appropriate solvent


Solvents for this reaction are those solvents or mixture of solvents which remain inert throughout the reaction. N, N-dimethylformamide, especially the anhydrous form thereof, is preferred.

The temperature employed in this step should be sufficient to effect completion of this alkylation reaction. Typically, ambient temperature is sufficient and preferred.

The present reaction preferably is run under an inert atmosphere, particularly nitrogen.

Under the preferred reaction conditions, this reaction will run to completion in about 16 to about 20 hours. Of course, the progress of the reaction can be monitored via standard chromatographic techniques.

As an alternative for preparing compounds of formula Ia, a formula IIb compound is reacted with an excess of an alkylating agent of the formula



wherein Q and Q' each are the same or different leaving group, in an alkali solution. Appropriate leaving groups include the sulfonates such as methanesulfonate, 4-bromobenzenesulfonate, toluenesulfonate, ethanesulfonate, isopropylsulfonate, 4-methoxybenzenesulfonate, 4-nitrobenzenesulfonate, 2-chlorobenzenesulfonate, triflate, and the like, halogens such as bromo, chloro, and iodo, and other related leaving groups. Aulogens are preferred leaving groups and bromo is especially preferred.

A preferred alkali solution for this alkylation reaction contains potassium carbonate in an inert solvent such as, for example, methyl ethyl ketone (MEK) or DMF. In this solution, the 4-hydroxy group of the benzoyl moiety of a formula IIb compound exists as a phenoxide ion which displaces one of the leaving groups of the alkylating agent.

This reaction is best when the alkali solution containing the reactants and reagents is brought to reflux and allowed to run to completion. When using MEK as the preferred solvent, reaction times run from about 6 hours to about 20 hours.

The reaction product from this step is then reacted with 1-piperidine, 1-pyrrolidine, methyl-1-pyrrolidine, dimethyl-1-pyrrolidine, 4-morpholine, dimethylamine, diethylamine, or 1-hexamethyleneimine, via standard techniques to form compounds of formula Ia. Preferably, the hydrochloride salt of piperidine is reacted with the alkylated compound of formula IIb in an inert solvent, such as anhydrous DMF, and heated to a temperature in the range from about 60° C to about 110° C. When the mixture is heated to a preferred temperature of about 90° C, the reaction only takes about 30 minutes to about 1 hour. However, changes in the reaction conditions will influence the amount of time this reaction needs to be run to completion. Of course, the progress of this reaction step can be monitored via standard chromatographic techniques.

Compounds of formula Ia, in which R<sup>5</sup> and/or R<sup>6</sup>, when present, are C<sub>1</sub>-C<sub>4</sub> alkyl, preferably methyl, are novel and are pharmaceutically active for the methods herein described. Accordingly, such compounds are encompassed by the definition herein of compounds of formula I.

Preferred compounds of formula I are obtained by cleaving, when present, the R<sup>5</sup> and R<sup>6</sup> hydroxy protecting groups of formula Ia compounds via well known procedures. Numerous reactions for the formation and removal of such protecting groups are described in a number of standard works including, for example, *Protective Groups in Organic Chemistry*, Plenum Press (London and New York, 1973), Green, T.W., *Protective Groups in Organic Synthesis*, Wiley, (New York, 1981), and *The Peptides*, Vol. I, Schroeder and Lubke, Academic Press (London and New York, 1965). Methods for removing preferred R<sup>5</sup> and/or R<sup>6</sup> hydroxy protecting groups, particularly methyl, are essentially as described in Example 5, *infra*.

Compounds of formula Ia are novel, are pharmaceutically active for the methods herein described, and are encompassed by formula I as defined herein.

Other preferred compounds of formula I are prepared by replacing the 6- and/or 4'-position hydroxy moieties, when present, with a moiety of the formula -O-CO-(C<sub>1</sub>-C<sub>6</sub> alkyl), or -O-SO<sub>2</sub>-(C<sub>2</sub>-C<sub>6</sub> alkyl) via well known procedures. See, e.g., U.S. Pat. No. 4,358,593.

For example, when an -O-CO-(C<sub>1</sub>-C<sub>6</sub> alkyl) group is desired, a mono- or dihydroxy compound of formula I is reacted with an agent such as acyl chloride, bromide, cyanide, or azide, or with an appropriate anhydride or mixed anhydride. The reactions are conveniently carried out in a basic solvent such as pyridine, lutidine, quinoline or isoquinoline, or in a tertiary amine solvent such as triethylamine, tributylamine, methylpiperidine, and the like. The reaction also may be carried out in an inert solvent such as ethyl acetate, dimethylformamide, dimethylsulfoxide, dioxane, dimethoxyethane, acetonitrile, acetone, methyl ethyl ketone, and the like, to which at least one equivalent of an acid scavenger (except as noted below), such as a tertiary amine, has been added. If desired, acylation catalysts such as 4-dimethylaminopyridine or 4-pyrrolidinopyridine may be used. See, e.g., Haslam, *et al.*, *Tetrahedron*, 36:2409-2433 (1980).

The present reactions are carried out at moderate temperatures, in the range from about -25° C to about 100° C, frequently under an inert atmosphere such as nitrogen gas. However, ambient temperature is usually adequate for the reaction to run.

Acylation of a 6-position and/or 4'-position hydroxy group also may be performed by acid-catalyzed reactions of the appropriate carboxylic acids in inert organic solvents. Acid catalysts such as sulfuric acid, polyphosphoric acid,

methanesulfonic acid, and the like are used

The aforementioned R<sup>1</sup> and/or R<sup>2</sup> groups of formula I compounds also may be provided by forming an active ester of the appropriate acid, such as the esters formed by such known reagents such as dicyclohexylcarbodiimide, acylimidazoles, nitrophenols, pentachlorophenol, N-hydroxysuccinimide, and 1-hydroxybenzotriazole. See, e.g., *Bull. Chem. Soc. Japan*, **38** 1979 (1965) and *Chem. Ber.*, 788 and 2024 (1970)

Each of the above techniques which provide -O-CO-(C<sub>1</sub>-C<sub>6</sub> alkyl) moieties are carried out in solvents as discussed above. Those techniques which do not produce an acid product in the course of the reaction, of course, do not call for the use of an acid scavenger in the reaction mixture.

When a formula I compound is desired in which the 6-and/or 4'-position hydroxy group of a formula I compound is converted to a group of the formula -O-SO<sub>2</sub>-(C<sub>2</sub>-C<sub>6</sub> alkyl), the mono- or dihydroxy compound is reacted with, for example, a sulfonic anhydride or a derivative of the appropriate sulfonic acid such as a sulfonyl chloride, bromide, or sulfonyl ammonium salt, as taught by King and Monoir *J. Am. Chem. Soc.*, **97** 2566-2567 (1975). The dihydroxy compound also can be reacted with the appropriate sulfonic anhydride or mixed sulfonic anhydrides. Such reactions are carried out under conditions such as were explained above in the discussion of reaction with acid halides and the like.

Although the free-base form of formula I compounds can be used in the methods of the present invention, it is preferred to prepare and use a pharmaceutically acceptable salt form. Thus, the compounds used in the methods of this invention primarily form pharmaceutically acceptable acid addition salts with a wide variety of organic and inorganic acids, and include the physiologically acceptable salts which are often used in pharmaceutical chemistry. Such salts are also part of this invention. Typical inorganic acids used to form such salts include hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, hypophosphoric, and the like. Salts derived from organic acids, such as aliphatic mono and dicarboxylic acids, phenyl substituted alkanic acids, hydroxyalkanoic and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, may also be used. Such pharmaceutically acceptable salts thus include acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, bromide, isobutyrate, phenylbutyrate, β-hydroxybutyrate, butyno-1,4-dioate, hexyno-1,4-dioate, caprate, caprylate, chloride, cinnamate, citrate, formate, fumarate, glycollate, heptanoate, hippurate, lactate, malate, maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, terephthalate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, propiolate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, sulfate, bisulfate, pyrosulfate, sulfite, bisulfite, sulfonate, benzenesulfonate, p-bromophenylsulfonate, chlorobenzenesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, methanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, p-toluenesulfonate, xylenesulfonate, tartarate, and the like. Preferred salts are the hydrochloride and oxalate salts.


The pharmaceutically acceptable acid addition salts are typically formed by reacting a compound of formula I with an equimolar or excess amount of acid. The reactants are generally combined in a mutual solvent such as diethyl ether or ethyl acetate. The salt normally precipitates out of solution within about one hour to 10 days and can be isolated by filtration or the solvent can be stripped off by conventional means.

The pharmaceutically acceptable salts generally have enhanced solubility characteristics compared to the compound from which they are derived, and thus are often more amenable to formulation as liquids or emulsions.

The following examples are presented to further illustrate the preparation of compounds of the present invention. It is not intended that the invention be limited in scope by reason of any of the following examples. NMR data for the following Examples were generated on a GE 300 MHz NMR instrument, and anhydrous d-6 DMSO was used as the solvent unless otherwise indicated.

#### Example 1

##### Preparation of [2-(4-methoxyphenyl)]-6-methoxynaphthyl-1-ol




6-methoxy-2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1(2H)-one (8.50 g, 30.14 mmol) was dissolved in 50 mL of isopropenyl acetate along with 1.0 g of p-toluenesulfonic acid. The resulting mixture was heated to reflux for 6 hours. Upon cooling to ambient temperature, 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (13.70 g, 60.28 mmol) was added. The reaction was then refluxed for 1.5 hours. After cooling to room temperature, the mixture was diluted with

methylene chloride (200 mL). The organic layer was washed with 0.2N sodium hydroxide (4 x 200 mL) followed by water (2 x 200 mL). The organic layer was dried (sodium sulfate) and concentrated *in vacuo* to a dark solid. The crude acetate was dissolved in 200 mL of 1:1 methanol:tetrahydrofuran and treated with excess sodium methoxide. An orange precipitate formed that was collected by filtration. The filtrate was acidified to pH = 4 with 5N hydrochloric acid. The filtrate was further diluted with 200 mL of water and then extracted with ethyl acetate (3 x 100 mL). The organic layer was dried (sodium sulfate) and concentrated *in vacuo* to an off-white solid. Crystallization from hexanes/ethyl acetate provided 4.24 g (50%) of [2-(4-methoxyphenyl)]-6-methoxynaphthyl-1-ol as a white solid. mp 129-131° C. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 8.19 (d, J = 9.1 Hz, 1H), 7.45 (d, J = 8.5 Hz, 2H), 7.38 (d, J = 8.0 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 7.18 (dd, J = 9.1, 2.8 Hz, 1H), 7.13 (d, J = 2.8 Hz, 1H), 7.07 (d, J = 8.5 Hz, 2H), 5.76 (bs, 1H), 3.94 (s, 3H), 3.88 (s, 3H). FD mass spec 280. Anal. Calcd for C<sub>18</sub>H<sub>16</sub>O<sub>3</sub>: C, 77.12; H, 5.75. Found: C, 76.83; H, 5.90.

### Example 2


#### Preparation of 1-(4-formyl)phenoxy-2-(4-methoxyphenyl)-6-methoxynaphthalene



To a solution of [2-(4-methoxyphenyl)]-6-methoxynaphthyl-1-ol (3.57 g, 12.75 mmol) in 180 mL of anhydrous N,N-dimethylformamide under N<sub>2</sub> at ambient temperature was added sodium hydride (535 mg, 13.38 mmol, 60% dispersion in mineral oil) in small portions. After stirring for 10 min, 4-fluorobenzaldehyde (3.20 g, 25.50 mmol) was added. The resulting mixture was heated to 70° C for 36 hours. Upon cooling to ambient temperature, the solvent was removed *in vacuo*. The residue was then distributed between ethyl acetate/water. The layers were separated and the organic was washed several times with water. The organic layer was finally dried (sodium sulfate) and concentrated *in vacuo* to an oil. Chromatography (90:10 hexanes/ethyl acetate) provided 2.06 g (48%) of 1-(4-formyl)phenoxy-2-(4-methoxyphenyl)-6-methoxynaphthalene as a white solid that was crystallized from methanol. Data for 1-(4-formyl)phenoxy-2-(4-methoxyphenyl)-6-methoxynaphthalene: mp 120-121° C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.80 (s, 1H), 7.78 (d, J = 9.2 Hz, 1H), 7.74 (d, J = 8.8 Hz, 1H), 7.67 (d, J = 8.8 Hz, 2H), 7.56 (d, J = 8.8 Hz, 1H), 7.46 (d, J = 8.8 Hz, 2H), 7.21 (d, J = 2.6 Hz, 1H), 7.12 (dd, J = 9.2, 2.6 Hz, 1H), 6.84 (d, J = 8.8 Hz, 2H), 6.81 (d, J = 8.8 Hz, 2H), 3.95 (s, 3H), 3.78 (s, 3H). FD mass spec 384. Anal. Calcd for C<sub>25</sub>H<sub>20</sub>O<sub>4</sub>: C, 78.11; H, 5.24. Found: C, 78.32; H, 5.24.

### Example 3

#### Preparation of 1-(4-hydroxy)phenoxy-2-(4-methoxyphenyl)-6-methoxynaphthalene




To a suspension of 1-(4-formyl)phenoxy-2-(4-methoxyphenyl)-6-methoxynaphthalene (2.70 g, 7.03 mmol) in 50 mL of methanol was added hydrogen peroxide (1.50 mL, 14.1 mmol, 30% solution) followed by concentrated sulfuric acid (0.5 mL). The reaction was gently warmed to aid dissolution then stirred at ambient temperature for 36 hours. Solid sodium bicarbonate was added to neutralize the acid, and the mixture was then distributed between ethyl acetate/

water (100 mL ea ) The layers were separated and the organic layer was dried (sodium sulfate) and concentrated *in vacuo* to a tan solid Chromatography (silicon dioxide 10-30% ethyl acetate/hexanes) provided 2.08 g (80%) of 1-(4-hydroxy)phenoxy-2-(4-methoxyphenyl)-6-methoxynaphthalene as a white solid mp 159-164° C <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 8.91 (s, 1H), 7.76 (d, J = 8.5 Hz, 1H), 7.69 (d, J = 9.2 Hz, 1H), 7.54 (d, J = 8.5 Hz, 1H), 7.48 (d, J = 8.7 Hz, 2H), 7.37 (d, J = 2.4 Hz, 1H), 7.09 (dd, J = 9.2, 2.4 Hz, 1H), 6.89 (d, J = 8.7 Hz, 2H), 6.47 (q, J<sub>AB</sub> = 9.0 Hz, 4H), 3.84 (s, 3H), 3.70 (s, 3H) FD mass spec 372 *Anal.* Calcd for C<sub>24</sub>H<sub>20</sub>O<sub>4</sub> C, 77.40, H, 5.41 Found C, 77.19, H, 5.70

#### Example 4


##### Preparation of 1-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-methoxyphenyl)-6-methoxynaphthalene hydrochloride



To a solution of 1-(4-hydroxy)phenoxy-2-(4-methoxyphenyl)-6-methoxynaphthalene (865 mg, 2.32 mmol) in 15 mL of anhydrous N,N-dimethylformamide under N<sub>2</sub> was added cesium carbonate (3.0 g, 9.2 mmol). After stirring for 15 minutes, 2-chloroethylpiperidine hydrochloride (540 mg, 2.90 mmol) was added. The resulting mixture was stirred vigorously for 24 hours, then distributed between ethyl acetate/water (200 mL ea ). The layers were separated, and the organic layer was washed several times with water. The organic layer was then dried (sodium sulfate) and concentrated *in vacuo* to a white solid. The crude free base was dissolved in 20 mL of ethyl acetate and treated with ethyl ether-hydrochloric acid. A precipitate formed that was collected by filtration and dried *in vacuo* to provide 1.06 g (88%) of 1-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-methoxyphenyl)-6-methoxynaphthalene hydrochloride as a white solid mp 184-188° C <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 9.91 (bs, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.71 (d, J = 9.2 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.54 (d, J = 8.8 Hz, 2H), 7.45 (d, J = 2.2 Hz, 1H), 7.15 (dd, J = 9.2, 2.2 Hz, 1H), 6.93 (d, J = 8.8 Hz, 2H), 6.82 (d, J = 9.1 Hz, 2H), 6.61 (d, J = 9.1 Hz, 2H), 4.21 (m, 2H), 3.89 (s, 3H), 3.75 (s, 3H), 3.45-3.33 (m, 4H), 2.92 (m, 2H), 1.80-1.63 (m, 5H), 1.35 (m, 1H) FD mass spec 483 *Anal.* Calcd for C<sub>31</sub>H<sub>33</sub>NO<sub>4</sub>·1.0 HCl C, 71.60, H, 6.59, N, 2.69 Found C, 71.77, H, 6.66, N, 2.79

#### Example 5

##### Preparation of 1-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)-6-hydroxynaphthalene hydrochloride



To a solution of 1-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-methoxyphenyl)-6-methoxynaphthalene hydrochloride (1.00 g, 1.92 mmol) in 20 mL of anhydrous methylene chloride under N<sub>2</sub> at 0° C was added boron tribromide (0.74 mL, 7.71 mmol). The resulting mixture was allowed to warm to 8° C and stirred for 2 hours. The reaction was then poured into a stirring solution of cold saturated sodium bicarbonate (200 mL). When gas evolution ceased, the aqueous layer was extracted with 5% methanol/chloroform (3 x 100 mL). The organic layer was combined, dried (sodium sulfate), and concentrated *in vacuo* to an oil. The crude free base was dissolved in 20 mL of ethyl acetate, and treated with

ethyl ether-hydrochloric acid. A precipitate formed that was collected by filtration. Drying *in vacuo* provided 798 mg (83%) of 1-[4-[2-(1-piperidinyl)ethoxy]-phenoxy]-2-(4-hydroxyphenyl)-6-hydroxynaphthalene hydrochloride as a white solid mp 130-136° C. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 9.89 (s, 1H), 9.80 (bs, 1H), 9.46 (s, 1H), 7.68 (d, J = 8.5 Hz, 1H), 7.64 (d, J = 9.2 Hz, 1H), 7.50 (d, J = 8.5 Hz, 1H), 7.40 (d, J = 8.8 Hz, 2H), 7.20 (d, J = 2.2 Hz, 1H), 7.04 (dd, J = 9.2, 2.2 Hz, 1H), 6.82 (d, J = 9.1 Hz, 2H), 6.76 (d, J = 8.8 Hz, 2H), 6.61 (d, J = 9.1 Hz, 2H), 4.21 (m, 2H), 3.45-3.33 (m, 4H), 2.92 (m, 2H), 1.80-1.63 (m, 5H), 1.35 (m, 1H). FD mass spec 456. Anal. Calcd for C<sub>29</sub>H<sub>29</sub>NO<sub>4</sub> · 1.0 HCl: C, 70.80, H, 6.15, N, 2.85. Found: C, 70.52, H, 6.19, N, 2.55.

## Test Procedure

### General Preparation Procedure

In the examples illustrating the methods, a post-menopausal model was used in which effects of different treatments upon circulating lipids were determined.

Seventy-five day old female Sprague Dawley rats (weight range of 200 to 225g) are obtained from Charles River Laboratories (Portage, MI). The animals are either bilaterally ovariectomized (OVX) or exposed to a Sham surgical procedure at Charles River Laboratories, and then shipped after one week. Upon arrival, they are housed in metal hanging cages in groups of 3 or 4 per cage and have *ad libitum* access to food (calcium content approximately 0.5%) and water for one week. Room temperature is maintained at 22.2° ± 1.7° C with a minimum relative humidity of 40%. The photoperiod in the room is 12 hours light and 12 hours dark.

### Dosing Regimen Tissue Collection

After a one week acclimation period (therefore, two weeks post-OVX) daily dosing with test compound is initiated. 17α-ethynyl estradiol or the test compound are given orally, unless otherwise stated, as a suspension in 1% carboxymethylcellulose or dissolved in 20% cyclodextrin. Animals are dosed daily for 4 days. Following the dosing regimen, animals are weighed and anesthetized with a ketamine Xylazine (2:1, V/V) mixture and a blood sample is collected by cardiac puncture. The animals are then sacrificed by asphyxiation with CO<sub>2</sub>, the uterus is removed through a midline incision, and a wet uterine weight is determined.

### Cholesterol Analysis

Blood samples are allowed to clot at ambient temperature for 2 hours, and serum is obtained following centrifugation for 10 minutes at 3000 rpm. Serum cholesterol is determined using a Boehringer Mannheim Diagnostics high performance cholesterol assay. Briefly, the cholesterol is oxidized to cholest-4-en-3-one and hydrogen peroxide. The hydrogen peroxide is then reacted with phenol and 4-aminophenazone in the presence of peroxidase to produce a p-quinone imine dye, which is read spectrophotometrically at 500 nm. Cholesterol concentration is then calculated against a standard curve. The entire assay is automated using a Biomek Automated Workstation.

### Uterine Eosinophil Peroxidase (EPO) Assay

Uteri are kept at 4° C until time of enzymatic analysis. The uteri are then homogenized in 50 volumes of 50 mM Tris buffer (pH = 8.0) containing 0.005% Triton X-100. Upon addition of 0.01% hydrogen peroxide and 10 mM O-phenylenediamine (final concentrations) in Tris buffer, increase in absorbance is monitored for one minute at 450 nm. The presence of eosinophils in the uterus is an indication of estrogenic activity of a compound. The maximal velocity of a 15 second interval is determined over the initial, linear portion of the reaction curve.

### Source of Compound

17α-ethynyl estradiol was obtained from Sigma Chemical Co. St. Louis, MO.

### Osteoporosis Test Procedure

Following the General Preparation Procedure, *infra*, the rats are treated daily for 35 days (6 rats per treatment group) and sacrificed by carbon dioxide asphyxiation on the 36th day. The 35 day time period is sufficient to allow maximal reduction in bone density, measured as described herein. At the time of sacrifice, the uteri are removed, dissected free of extraneous tissue, and the fluid contents are expelled before determination of wet weight in order to confirm estrogen deficiency associated with complete ovariectomy. Uterine weight is routinely reduced about 75% in

response to ovariectomy. The uteri are then placed in 10% neutral buffered formalin to allow for subsequent histological analysis.

The right femurs are excised and digitized x-rays generated and analyzed by an image analysis program (NIH image) at the distal metaphysis. The proximal aspect of the tibiae from these animals are also scanned by quantitative computed tomography.

In accordance with the above procedures, compounds of the present invention and ethynyl estradiol (EE<sub>2</sub>) in 20% hydroxypropyl  $\beta$ -cyclodextrin are orally administered to test animals.

#### MCF-7 Proliferation Assay

MCF-7 breast adenocarcinoma cells (ATCC HTB 22) are maintained in MEM (minimal essential medium, phenol red-free, Sigma St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) (V/V), L-glutamine (2 mM), sodium pyruvate (1 mM), HEPES ((N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid])10 mM) non-essential amino acids and bovine insulin (1  $\mu$ g/mL) (maintenance medium). Ten days prior to assay, MCF-7 cells are switched to maintenance medium supplemented with 10% dextran coated charcoal stripped fetal bovine serum (DCC-FBS) assay medium) in place of 10% FBS to deplete internal stores of steroids. MCF-7 cells are removed from maintenance flasks using cell dissociation medium (Ca<sup>++</sup>/Mg<sup>++</sup> free HBSS (phenol red-free) supplemented with 10 mM HEPES and 2 mM EDTA). Cells are washed twice with assay medium and adjusted to 80,000 cells/mL. Approximately 100  $\mu$ L (8,000 cells) are added to flat-bottom microculture wells (Costar 3596) and incubated at 37° C in a 5% CO<sub>2</sub> humidified incubator for 48 hours to allow for cell adherence and equilibration after transfer. Serial dilutions of drugs or DMSO as a diluent control are prepared in assay medium and 50  $\mu$ L transferred to triplicate microcultures followed by 50  $\mu$ L assay medium for a final volume of 200  $\mu$ L. After an additional 48 hours at 37° C in a 5% CO<sub>2</sub> humidified incubator, microcultures are pulsed with tritiated thymidine (1  $\mu$ Ci/well) for 4 hours. Cultures are terminated by freezing at -70° C for 24 hours followed by thawing and harvesting of microcultures using a Skatron Semiautomatic Cell Harvester. Samples are counted by liquid scintillation using a Wallac BetaPlace  $\beta$  counter. Activity of a compound of formula I in the present assay demonstrates that the compound is of potential for treating hormonally-dependent cancer, particularly breast cancer.

#### DMBA-Induced Mammary Tumor Inhibition

Estrogen-dependent mammary tumors are produced in female Sprague-Dawley rats which are purchased from Harlan Industries, Indianapolis, Indiana. At about 55 days of age, the rats receive a single oral feeding of 20 mg of 7,12-dimethylbenz[a]anthracene (DMBA). About 6 weeks after DMBA administration, the mammary glands are palpated at weekly intervals for the appearance of tumors. Whenever one or more tumors appear, the longest and shortest diameters of each tumor are measured with a metric caliper, the measurements are recorded, and that animal is selected for experimentation. An attempt is made to uniformly distribute the various sizes of tumors in the treated and control groups such that average-sized tumors are equivalently distributed between test groups. Control groups and test groups for each experiment contain 5 to 9 animals.

Compounds of Formula I are administered either through intraperitoneal injections in 2% acacia, or orally. Orally administered compounds are either dissolved or suspended in 0.2 mL corn oil. Each treatment, including acacia and corn oil control treatments, is administered once daily to each test animal. Following the initial tumor measurement and selection of test animals, tumors are measured each week by the abovementioned method. The treatment and measurements of animals continue for 3 to 5 weeks at which time the final areas of the tumors are determined. For each compound and control treatment, the change in the mean tumor area is determined.

#### Uterine Fibrosis Test Procedures

##### Test 1

Between 3 and 20 women having uterine fibrosis are administered a compound of the present invention. The amount of compound administered is from 0.1 to 1000 mg/day, and the period of administration is 3 months.

The women are observed during the period of administration, and up to 3 months after discontinuance of administration, for effects on uterine fibrosis.

##### Test 2

The same procedure is used as in Test 1, except the period of administration is 6 months.



Test 3

The same procedure is used as in Test 1, except the period of administration is 1 year

5 Test 4

## A Induction of fibroid tumors in guinea pig

10 Prolonged estrogen stimulation is used to induce leiomyomata in sexually mature female guinea pigs. Animals are dosed with estradiol 3-5 times per week by injection for 2-4 months or until tumors arise. Treatments consisting of a compound of the invention or vehicle is administered daily for 3-16 weeks and then animals are sacrificed and the uteri harvested and analyzed for tumor regression.

## 15 B Implantation of human uterine fibroid tissue in nude mice

Tissue from human leiomyomas are implanted into the peritoneal cavity and or uterine myometrium of sexually mature, castrated, female, nude mice. Exogenous estrogen are supplied to induce growth of the explanted tissue. In some cases, the harvested tumor cells are cultured *in vitro* prior to implantation. Treatment consisting of a compound of the present invention or vehicle is supplied by gastric lavage on a daily basis for 3-16 weeks and implants are removed and measured for growth or regression. At the time of sacrifice, the uteri is harvested to assess the status of the organ.

20 Test 5

25 A Tissue from human uterine fibroid tumors is harvested and maintained, *in vitro*, as primary nontransformed cultures. Surgical specimens are pushed through a sterile mesh or sieve, or alternately teased apart from surrounding tissue to produce a single cell suspension. Cells are maintained in media containing 10% serum and antibiotic. Rates of growth in the presence and absence of estrogen are determined. Cells are assayed for their ability to produce complement component C3 and their response to growth factors and growth hormone. *In vitro* cultures are assessed for their proliferative response following treatment with progestins, GnRH, a compound of the present invention and vehicle. Levels of steroid hormone receptors are assessed weekly to determine whether important cell characteristics are maintained *in vitro*. Tissue from 5-25 patients are utilized.

Activity in at least one of the above tests indicates the compounds of the present invention are of potential in the treatment of uterine fibrosis.

35

Endometriosis Test Procedure

In Tests 1 and 2, effects of 14-day and 21-day administration of compounds of the present invention on the growth of explanted endometrial tissue can be examined.

40

Test 1

Twelve to thirty adult CD strain female rats are used as test animals. They are divided into three groups of equal numbers. The estrous cycle of all animals is monitored. On the day of proestrus, surgery is performed on each female. Females in each group have the left uterine horn removed, sectioned into small squares, and the squares are loosely sutured at various sites adjacent to the mesenteric blood flow. In addition, females in Group 2 have the ovaries removed.

On the day following surgery, animals in Groups 1 and 2 receive intraperitoneal injections of water for 14 days whereas animals in Group 3 receive intraperitoneal injections of 1.0 mg of a compound of the present invention per kilogram of body weight for the same duration. Following 14 days of treatment, each female is sacrificed and the endometrial explants, adrenals, remaining uterus, and ovaries, where applicable, are removed and prepared for histological examination. The ovaries and adrenals are weighed.

50 Test 2

Twelve to thirty adult CD strain female rats are used as test animals. They are divided into two equal groups. The estrous cycle of all animals is monitored. On the day of proestrus, surgery is performed on each female. Females in each group have the left uterine horn removed, sectioned into small squares, and the squares are loosely sutured at various sites adjacent to the mesenteric blood flow.

Approximately 50 days following surgery, animals assigned to Group 1 receive intraperitoneal injections of water for 21 days whereas animals in Group 2 receive intraperitoneal injections of 10 mg of a compound of the present invention per kilogram of body weight for the same duration. Following 21 days of treatment, each female is sacrificed and the endometrial explants and adrenals are removed and weighed. The explants are measured as an indication of growth. Estrous cycles are monitored.

### Test 3

#### A Surgical induction of endometriosis

Autographs of endometrial tissue are used to induce endometriosis in rats and/or rabbits. Female animals at reproductive maturity undergo bilateral oophorectomy, and estrogen is supplied exogenously thus providing a specific and constant level of hormone. Autologous endometrial tissue is implanted in the peritoneum of 5-150 animals and estrogen supplied to induce growth of the explanted tissue. Treatment consisting of a compound of the present invention is supplied by gastric lavage on a daily basis for 3-16 weeks, and implants are removed and measured for growth or regression. At the time of sacrifice, the intact horn of the uterus is harvested to assess status of endometrium.

#### B Implantation of human endometrial tissue in nude mice

Tissue from human endometrial lesions is implanted into the peritoneum of sexually mature, castrated, female nude mice. Exogenous estrogen is supplied to induce growth of the explanted tissue. In some cases the harvested endometrial cells are cultured *in vitro* prior to implantation. Treatment consisting of a compound of the present invention supplied by gastric lavage on a daily basis for 3-16 weeks and implants are removed and measured for growth or regression. At the time of sacrifice, the uteri are harvested to assess the status of the intact endometrium.

### Test 4

A Tissue from human endometrial lesions is harvested and maintained *in vitro* as primary nontransformed cultures. Surgical specimens are pushed through a sterile mesh or sieve or alternately teased apart from surrounding tissue to produce a single cell suspension. Cells are maintained in media containing 10% serum and antibiotic. Rates of growth in the presence and absence of estrogen are determined. Cells are assayed for their ability to produce complement component C3 and their response to growth factors and growth hormone. *In vitro* cultures are assessed for their proliferative response following treatment with progestins, GnRH, a compound of the invention, and vehicle. Levels of steroid hormone receptors are assessed weekly to determine whether important cell characteristics are maintained *in vitro*. Tissue from 5-25 patients is utilized.

Activity in any of the above assays indicates that the compounds of the present invention are useful in the treatment of endometriosis.

#### Inhibition of Aortal Smooth Cell Proliferation/Restenosis Test Procedure

Compounds of the present invention have capacity to inhibit aortal smooth cell proliferation. This can be demonstrated by using cultured smooth cells derived from rabbit aorta, proliferation being determined by the measurement of DNA synthesis. Cells are obtained by explant method as described in Ross, *J. of Cell Bio* 50: 172 (1971). Cells are plated in 96 well microtiter plates for five days. The cultures become confluent and growth arrested. The cells are then transferred to Dulbecco's Modified Eagle's Medium (DMEM) containing 0.5 - 2% platelet poor plasma, 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 1 mCi/ml <sup>3</sup>H-thymidine, 20 ng/ml platelet-derived growth factor and varying concentrations of the present compounds. Stock solution of the compounds is prepared in dimethyl sulphoxide and then diluted to appropriate concentration (0.01 - 30 mM) in the above assay medium. Cells are then incubated at 37° C. for 24 hours under 5% CO<sub>2</sub>/95% air. At the end of 24 hours the cells are fixed in methanol. <sup>3</sup>H thymidine incorporation in DNA is then determined by scintillation counting as described in Bonin, *et al*, *Exp. Cell Res* 181: 475-482 (1989).

Inhibition of aortal smooth muscle cell proliferation by the compounds of the present invention are further demonstrated by determining their effects on exponentially growing cells. Smooth muscle cells from rabbit aortae are seeded in 12 well tissue culture plates in DMEM containing 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. After 24 hours the cells are attached and the medium is replaced with DMEM containing 10% serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, and desired concentrations of the compounds. Cells are allowed to grow for four days. Cells are treated with trypsin and the number of cells in each culture is determined by counting using a ZM-Coulter counter.

Activity in the above tests indicates that the compounds of the present invention are of potential in the treatment of restenosis

The present invention also provides a method of alleviating post-menopausal syndrome in women which comprises the aforementioned method using compounds of Formula I and further comprises administering to a woman an effective amount of estrogen or progestin. These treatments are particularly useful for treating osteoporosis and lowering serum cholesterol because the patient will receive the benefits of each pharmaceutical agent while the compounds of the present invention would inhibit undesirable side-effects of estrogen and progestin. Activity of these combination treatments in any of the post-menopausal tests, *infra*, indicates that the combination treatments are useful for alleviating the symptoms of post-menopausal symptoms in women.

Various forms of estrogen and progestin are commercially available. Estrogen-based agents include, for example, ethynyl estrogen (0.01 - 0.03 mg/day), mestranol (0.05 - 0.15 mg/day), and conjugated estrogenic hormones such as Premarin® (Wyeth-Ayerst 0.3 - 2.5 mg/day). Progestin-based agents include, for example, medroxyprogesterone such as Provera® (Upjohn, 2.5 - 10 mg/day), norethynodrel (1.0 - 10.0 mg/day), and norethindrone (0.5 - 2.0 mg/day). A preferred estrogen-based compound is Premarin, and norethynodrel and norethindrone are preferred progestin-based agents.

The method of administration of each estrogen- and progestin-based agent is consistent with that which is known in the art. For the majority of the methods of the present invention, compounds of Formula I are administered continuously from 1 to 3 times daily. However, cyclical therapy may especially be useful in the treatment of endometriosis or may be used acutely during painful attacks of the disease. In the case of restenosis, therapy may be limited to short (1-6 months) intervals following medical procedures such as angioplasty.

As used herein the term "effective amount" means an amount of compound of the present invention which is capable of alleviating the symptoms of the various pathological conditions herein described. The specific dose of a compound administered according to this invention will, of course, be determined by the particular circumstances surrounding the case including, for example, the compound administered, the route of administration, the state of being of the patient, and the pathological condition being treated. A typical daily dose will contain a nontoxic dosage level of from about 5 mg to about 600 mg/day of a compound of the present invention. Preferred daily doses generally will be from about 15 mg to about 80 mg/day.

The compounds of this invention can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. These compounds preferably are formulated prior to administration, the selection of which will be decided by the attending physician. Thus, another aspect of the present invention is a pharmaceutical composition comprising an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, optionally containing an effective amount of estrogen or progestin, and a pharmaceutically acceptable carrier, diluent, or excipient.

The total active ingredients in such formulations comprises from 0.1% to 99.9% by weight of the formulation. By "pharmaceutically acceptable" it is meant the carrier, diluent, excipients and salt must be compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof.

Pharmaceutical formulations of the present invention can be prepared by procedures known in the art using well known and readily available ingredients. For example, the compounds of formula I, with or without an estrogen or progestin compound, can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, suspensions, powders, and the like. Examples of excipients, diluents, and carriers that are suitable for such formulations include the following: fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinylpyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as calcium carbonate and sodium bicarbonate; agents for retarding dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate; adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate, and solid polyethyl glycols.

The compounds also can be formulated as elixirs or solutions for convenient oral administration or as solutions appropriate for parenteral administration, for example, by intramuscular, subcutaneous or intravenous routes. Additionally, the compounds are well suited to formulation as sustained release dosage forms and the like. The formulations can be so constituted that they release the active ingredient only or preferably in a particular physiological location, possibly over a period of time. The coatings, envelopes, and protective matrices may be made, for example, from polymeric substances or waxes.

Compounds of formula I, alone or in combination with a pharmaceutical agent of the present invention, generally will be administered in a convenient formulation. The following formulation examples only are illustrative and are not intended to limit the scope of the present invention.

Formulations

In the formulations which follow, "active ingredient" means a compound of formula I, or a salt or solvate thereof

Formulation 1 Gelatin Capsules

Hard gelatin capsules are prepared using the following

Ingredient	Quantity (mg/capsule)
Active ingredient	0.01 - 1000
Starch, NF	0 - 650
Starch flowable powder	0 - 650
Silicone fluid 350 centistokes	0 - 15

The formulation above may be changed in compliance with the reasonable variations provided  
A tablet formulation is prepared using the ingredients below

Formulation 2 Tablets

Ingredient	Quantity (mg/tablet)
Active ingredient	2.5 - 1000
Cellulose, microcrystalline	200 - 650
Silicon dioxide, fumed	10 - 650
Stearate acid	5 - 15

The components are blended and compressed to form tablets

Alternatively, tablets each containing 2.5 - 1000 mg of active ingredient are made up as follows Formulation 3  
Tablets

Ingredient	Quantity (mg/tablet)
Active ingredient	25 - 1000
Starch	45
Cellulose microcrystalline	35
Polyvinylpyrrolidone (as 10 % solution in water)	4
Sodium carboxymethyl cellulose	4.5
Magnesium stearate	0.5
Talc	1

The active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50°-60° C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 60 U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets.

Suspensions each containing 0.1 - 1000 mg of medicament per 5 ml dose are made as follows

Formulation 4 Suspensions

Ingredient	Quantity (mg/5 ml)
Active ingredient	0.1 - 1000 mg
Sodium carboxymethyl cellulose	50 mg
Syrup	1.25 mg

(continued)

Ingredient	Quantity (mg/5 ml)
Benzoic acid solution	0.10 mL
Flavor	q.v.
Color	q.v.
Purified water to	5 mL

The medicament is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor, and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume.

An aerosol solution is prepared containing the following ingredients:

#### Formulation 5 Aerosol

Ingredient	Quantity (% by weight)
Active ingredient	0.25
Ethanol	25.75
Propellant 22 (Chlorodifluoromethane)	70.00

The active ingredient is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to 30°C, and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remaining propellant. The valve units are then fitted to the container.

Suppositories are prepared as follows:

#### Formulation 6 Suppositories

Ingredient	Quantity (mg/suppository)
Active ingredient	250
Saturated fatty acid glycerides	2,000

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimal necessary heat. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.

An intravenous formulation is prepared as follows:

#### Formulation 7 Intravenous Solution

Ingredient	Quantity
Active ingredient	50 mg
Isotonic saline	1,000 mL

The solution of the above ingredients is intravenously administered to a patient at a rate of about 1 mL per minute.

#### Formulation 8 Combination Capsule I

Ingredient	Quantity (mg/capsule)
Active ingredient	50
Premarin	1

(continued)

Ingredient	Quantity (mg/capsule)
Avicel pH 101	50
Starch 1500	117.50
Silicon Oil	2
Twcen 80	0.50
Cab-O-Sil	0.25

Formulation 9 Combination Capsule II


Ingredient	Quantity (mg/capsule)
Active ingredient	50
Norethynodrel	5
Avicel pH 101	82.50
Starch 1500	90
Silicon Oil	2
Twcen 80	0.50

Formulation 10 Combination Tablet

Ingredient	Quantity (mg/capsule)
Active ingredient	50
Premarin	1
Corn Starch NF	50
Povidone K29-32	6
Avicel pH 101	41.50
Avicel pH 102	136.50
Crospovidone XL10	2.50
Magnesium Stearate	0.50
Cab-O-Sil	0.50

**Claims**

1. A compound of formula I



wherein

R<sup>1</sup> is -H, -OH, -O(C<sub>1</sub>-C<sub>4</sub> alkyl), -OCOC<sub>6</sub>H<sub>5</sub>, -OCO(C<sub>1</sub>-C<sub>6</sub> alkyl), or -OSO<sub>2</sub>(C<sub>2</sub>-C<sub>6</sub> alkyl),

R<sup>2</sup> is -H, -OH, -O(C<sub>1</sub>-C<sub>4</sub> alkyl), -OCOC<sub>6</sub>H<sub>5</sub>, -OCO(C<sub>1</sub>-C<sub>6</sub> alkyl), -OSO<sub>2</sub>(C<sub>2</sub>-C<sub>6</sub> alkyl), -or halo,

R<sup>3</sup> is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidino, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino and

n is 2 or 3 and

or a pharmaceutically acceptable salt thereof

2. A compound according to Claim 1 wherein

R<sup>1</sup> is -OH,

R<sup>2</sup> is -OH,

R<sup>3</sup> is 1-piperidinyl, and


n is 2

or a pharmaceutically acceptable salt thereof

3. A compound according to Claim 2 wherein said salt thereof is the hydrochloride salt

4. A pharmaceutical formulation comprising as an active ingredient a compound as claimed in any one of Claims 1 to 3, and, optionally, estrogen or progestin, associated with one or more pharmaceutically acceptable carriers, excipients, or diluents therefor

5. A compound of formula II



wherein

R<sup>1a</sup> is -H or -OR<sup>5</sup> in which R<sup>5</sup> is a hydroxy protecting group

R<sup>2a</sup> is -H, halo, or -OR<sup>6</sup> in which R<sup>6</sup> is a hydroxy protecting group, and

R<sup>4</sup> is -OH or -CHO,

or a pharmaceutically acceptable salt thereof

6. A compound according to Claim 5 wherein R<sup>1a</sup> is -OR<sup>5</sup> in which R<sup>5</sup> is methyl, and R<sup>2a</sup> is -OR<sup>6</sup> in which R<sup>6</sup> is methyl


7. A compound according to Claim 6 wherein R<sup>4</sup> is -OH, or a pharmaceutically acceptable salt thereof.

8. A compound as claimed in any one of Claims 5 to 7 wherein said salt thereof is the hydrochloride salt

9. A process for preparing a compound of formula I, or a pharmaceutically acceptable salt thereof, as claimed in any one of Claims 1 to 3 comprising


a)

(A) reacting a compound of formula IIb



wherein

$R^{1a}$  is -H or -OR<sup>5</sup> in which R<sup>5</sup> is a hydroxy protecting group and  
 $R^{2a}$  is -H, halo, or -OR<sup>6</sup> in which R<sup>6</sup> is a hydroxy protecting group, with a compound of formula V




V


wherein

$R^3$  is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino, and  
 Q is a leaving group, or

(B) reacting a compound of formula IIb



wherein  $R^{1a}$  and  $R^{2a}$  are as defined above, with an alkylating agent of the formula



wherein Q and Q' is the same or different leaving group, the product of which is then reacted with  
 1-piperidine, 1-pyrrolidine, methyl-1-pyrrolidine, dimethyl-1-pyrrolidine, 4-morpholine, dimethylamine,  
 diethylamine, diisopropylamine, or 1-hexamethyleneimino,

b) optionally removing the remaining hydroxy protecting group or groups, and  
 c) optionally forming a salt of the product of step a) or step b)

10. A compound of formula I as claimed in any one of Claims 1 to 3 for use as an agent for alleviating the symptoms of postmenopausal syndrome
11. A compound according to Claim 10 wherein said postmenopausal syndrome condition is osteoporosis, a related cardiovascular disease, hyperlipidemia, or hormonally-dependent cancer
12. A compound of formula I as claimed in any one of Claims 1 to 3 for use as an agent for inhibiting uterine fibroid disease, endometriosis, aortal smooth muscle cell proliferation, or restenosis





European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 96 30 0877

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
A	US-A-5 147 880 (CHARLES D. JONES) 15 September 1992 * the whole document *	1-12	C07D295/08 C07C43/295 C07C47/575 A61K31/445
A	US-A-4 230 862 (TULIO SUAREZ ET AL.) 28 October 1980 * the whole document *	1-12	
A	EP-A-0 065 692 (KLINGE PHARMA) 1 December 1982 * claims; examples *	1-12	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int.Cl.6)  C07D C07C
Place of search THE HAGUE		Date of completion of the search 4 June 1996	Examiner Zervas, B
CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention F: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons &: member of the same patent family, corresponding document			

PPO FORM 1303 (03.11.1994)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**